相关实验视频
Updated: Jun 11, 2025
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
6.9K
预测与细胞衰老相关的lncRNAs模式,以预测结肠癌的临床结果和免疫反应
Lichao Cao1,2,3, Fang Chen1,2,3, Long Xu4,5
1Shenzhen Nucleus Gene Technology Co., Ltd., Shenzhen, Guangdong, China.
Frontiers in immunology
|October 2, 2024
概括
细胞衰老相关的lncRNAs (CSRLs) 可以预测结肠癌的预后和免疫治疗反应. 确定了包括MYOSLID在内的3-CSRL模型,为结肠癌患者提供了潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 细胞衰老 (CS) 与癌症的发展有关.
- 与CS相关的长非编码RNAs (CSRLs) 在结肠癌中的作用尚未完全理解.
- 确定结肠癌预后和治疗的新生物标志物至关重要.
研究的目的:
- 为结肠癌开发基于CSRLs的预后模型.
- 预测患者的预后和对免疫治疗的反应.
- 探索关键的CSRLs在结肠癌中的分子功能.
主要方法:
- 使用的TCGA结肠癌 (TCGA-COAD) mRNA测序数据.
- 使用皮尔森相关性分析确定了CSRLs.
- 通过LASSO和Cox回归分析开发了一个预后模型.
- 使用生存率和ROC曲线分析评估模型性能.
- 评估瘤微环境,突变,免疫治疗和药物敏感性.
- 通过细胞实验验证了MYOSLID的功能.
主要成果:
- 确定了三个预后性的CSRLs:AC025165.1,LINC02257和MYOSLID.
- 3-CSRL预后模型准确预测了整体存活率和临床病理特征.
- 风险组之间观察到免疫细胞比例和免疫抑制标志物的显著差异.
- 高风险患者从Teniposide和Mitoxantrone等化疗药物中获益.
- MYOSLID knockdown抑制了结肠癌细胞的增殖和衰老.
结论:
- CSRLs作为有价值的生物标志物,用于预测结肠癌的生存率和治疗反应.
- 鉴定的3-CSRL模型显示出显著的预后和预测价值.
- 米奥斯利德在调节结肠癌细胞增殖和衰老方面发挥着至关重要的作用,这表明其具有治疗潜力.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.2K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
01:21Cancer Survival Analysis
329
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
329
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K